Candel Therapeutics (CADL) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
26 Jun, 2026Opening remarks and agenda
The meeting was called to order by the CEO, with legal counsel recording the minutes and formal business outlined as per the notice and proxy statement.
Stockholders were welcomed, and the meeting was held in accordance with bylaws and Delaware law.
Additional directors, executive team, audit firm, and legal representatives were introduced.
Rules of conduct and voting eligibility were explained, with instructions for submitting questions and voting.
Board and executive committee updates
Four nominees for Class II directors were presented for election to serve a three-year term, with no additional nominations received.
Corporate governance
An independent inspector of election was appointed to oversee and tabulate voting results.
The audit committee, composed entirely of independent directors, appointed KPMG LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
Latest events from Candel Therapeutics
- Net loss rose on higher R&D and commercial costs; cash supports operations into Q1 2028.CADL
Q2 2026 - Aglatimagene shows strong efficacy in prostate cancer, with major regulatory and commercial momentum.CADL
Canaccord Genuity's 46th Annual Growth Conference - Aglatimagene and linoserpaturev show strong efficacy and safety in late-stage oncology trials.CADL
Corporate presentation - Lead viral immunotherapies deliver strong efficacy in solid tumors, with pivotal trials and filings ahead.CADL
Jefferies Global Healthcare Conference 2026 - Aglatimagene achieved significant disease-free survival in prostate cancer, with BLA filing on track.CADL
Stifel 2026 Targeted Oncology Virtual Forum - Aglatimagene plus radiotherapy improved disease-free survival by 39% and reduced recurrence risk.CADL
Study result - Aglatimagene and linoserpaturev show strong efficacy and safety across multiple cancer indications.CADL
Corporate presentation - Lead programs show strong efficacy and safety across major cancers, with broad market potential.CADL
Corporate presentation - Late-stage immunotherapy programs advance toward commercialization and regulatory milestones.CADL
R&D Day 2025